GlassScriptPhysician profile
Chirag J Amin
NPI 1093830176
$5,061.20
in general payments reported to CMS, 2019-2025
56 companies · $1,950 in 2025
The $1,950 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $166 · 2021: $24.38 · 2022: $196 · 2023: $1,018 · 2024: $1,246 · 2025: $1,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,105 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,104.93 |
| Education | $109.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $721.71 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $638.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $416.52 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Pfizer INC. | $293.32 | 2019-2025 | |
| Astellas Pharma US INC | $255.20 | 2019-2025 | Vyloy, Padcev, Xospata |
| Celgene Corporation | $237.06 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $231.13 | 2023-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $138.37 | 2019-2024 | Imbruvica, Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $136.48 | 2019-2024 | Opdivo |
| Gilead Sciences, INC. | $124.05 | 2019-2023 | Trodelvy |
| Genzyme Corporation | $122.13 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $102.01 | 2023-2024 | Libtayo |
| Abbvie INC. | $100.14 | 2023-2024 | Venclexta |
| Genentech USA, INC. | $95.23 | 2020-2025 | Tecentriq, Columvi |
| Rigel Pharmaceuticals, INC. | $79.11 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chirag Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.